Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.
COVID-19
SARS-CoV-2
antibody
bamlanivimab
vaccine failure
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
14
07
2021
accepted:
06
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.
Identifiants
pubmed: 34557558
doi: 10.1093/ofid/ofab420
pii: ofab420
pmc: PMC8454518
doi:
Banques de données
ClinicalTrials.gov
['NCT04362995']
Types de publication
Journal Article
Langues
eng
Pagination
ofab420Investigateurs
Ericka Kirkpatrick Roubidoux
(E)
Pamela Freiden
(P)
Tomi Mori
(T)
Diego R Hijano
(DR)
Hana Hakim
(H)
David C Brice
(DC)
Ashley Castellaw
(A)
Florian Krammer
(F)
David E Wittman
(DE)
Jason Hodges
(J)
Ronald H Dallas
(RH)
Valerie Cortez
(V)
Ana Vazquez-Pagan
(A)
Resha Bajracharya
(R)
Brandi L Clark
(BL)
Lee-Ann Van de Velde
(LA)
Walid Awad
(W)
Taylor L Wilson
(TL)
Allison M Kirk
(AM)
Randall T Hayden
(RT)
James Hoffman
(J)
Jamie Russell-Bell
(J)
James Sparks
(J)
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Virol. 2021 Jun 24;95(14):e0040421
pubmed: 33893169
J Pediatr. 1993 Feb;122(2):204-11
pubmed: 8429432
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876